NCT06477536View on ClinicalTrials.gov

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 2, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Generalized Pustular Psoriasis
Interventions
DRUG

HB0034

300mg, i.v. Q4W

Trial Locations (3)

Unknown

RECRUITING

Peking University People's Hospital (PKUPH), Beijing

RECRUITING

Peking University People's Hospital, Beijing

RECRUITING

The Second affiliated Hospital zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Shanghai Huaota Biopharmaceutical Co., Ltd.

INDUSTRY